Cognivia Raises €15.5M to Accelerate AI Solutions for Clinical Trials
Cognivia Secures Strategic €15.5M Funding
Cognivia Raises €15.5M in Funding
Key Highlights:
- Funding: Cognivia, an AI company focused on pharmaceutical and biotech clinical research, raised €15.5M in funding.
- Investors: Vesalius Biocapital IV, SFPIM, and WE participated in the funding round.
- Predictive Clinical Trial Solutions: Cognivia will use the funds to deploy its solutions that use AI and machine learning to decode the relationship between patient traits and behaviors, expediting the development of innovative treatments.
Cognivia's Target Market
- Pharmaceutical and Biotech Companies: Targeting companies in the pharmaceutical and biotech industries that conduct clinical trials and develop innovative treatments.
- Clinicians and Researchers: Providing tools and solutions to empower clinicians and researchers in making data-driven decisions and improving therapeutic efficacy in clinical trials.
- Global Patient Population: Ultimately aiming to enhance outcomes for patients worldwide through the development of innovative treatments.
What Cognivia Needs to Buy
- AI and Machine Learning Expertise: Collaborating with experts in AI and machine learning to enhance their predictive algorithms and technologies.
- Partnerships with Clinical Research Organizations: Collaborating with CROs to integrate their predictive clinical trial solutions into ongoing research projects.
- Expansion of Operational Team: Hiring additional team members to support the deployment and implementation of their solutions.